Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.59 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.59 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.59 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.59 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8413718 | 1.00 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5251164 | 0.98 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL891670 | 0.91 | GRIN2D (0.60) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1425463 | 0.88 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10957944 | 0.85 | GRIN2D (0.76) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2757 | 0.80 | GRIN2D (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9240799 | 0.79 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8947159 | 0.77 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1149893 | 0.77 | GRIN2D (0.95) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9242137 | 0.77 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390246-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-12-07 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230105307-A1 | Identification of Stabilizers of Multimeric Proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-04-06 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| US-11337935-B2 | Identification of stabilizers of multimeric proteins | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-05-24 | — | — | US | disclosed |
| EP-3935042-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | Conatus Pharmaceuticals, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| US-11136362-B2 | Peptide modulators of specific calcineurin protein-protein interactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | Alhamadsheh, Mamoun M. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210277014-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | HISTOGEN, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-0877736-A1 | BENZAZEPINE DERIVATIVES WITH VASOPRESSIN AGONISTIC ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-18 | — | — | EP | disclosed |
| EP-0874850-A1 | NOVEL TRICYCLIC COMPOUNDS FOR THE INHIBITION OF THE ICE/CED-3 PROTEASE FAMILY OF ENZYMES | Idun Pharmaceuticals, Inc. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998034603-A1 | USE OF BETULIN AND ANALOGS THEREOF TO TREAT HERPESVIRUS INFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-08-13 | — | — | WO | disclosed |
| WO-1998010778-A1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998011109-A1 | NOVEL TRICYCLIC COMPOUNDS FOR THE INHIBITION OF THE ICE/CED-3 PROTEASE FAMILY OF ENZYMES | IDUN PHARMACEUTICALS, INCORPORATED (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998011129-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INCORPORATED (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1997022591-A1 | BENZAZEPINE DERIVATIVES WITH VASOPRESSIN AGONISTIC ACTIVITY | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-06-26 | — | — | WO | disclosed |
| CN-1150799-A | Benzoheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 1997-05-28 | — | — | CN | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105307-A1 | Identification of Stabilizers of Multimeric Proteins | TTR, HSPBP1, HSPH1 | GRIN2D 3899/4885GRIN3B 3938/4885GRIN1 3510/4885 |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | GRIN2D 4446/4885GRIN3B 3295/4885GRIN1 3070/4885 |
| US-20210277014-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | CASP1, CASP3, CASP6 | GRIN2D 3907/4885GRIN3B 2375/4885GRIN1 3204/4885 |
| US-20220202837-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | PTMS, QPCT, ANPEP | GRIN2D 3405/4885GRIN3B 1209/4885GRIN1 3209/4885 |
| US-11337935-B2 | Identification of stabilizers of multimeric proteins | TTR, HSPBP1, HSPH1 | GRIN2D 3899/4885GRIN3B 3938/4885GRIN1 3510/4885 |
| US-20230390246-A1 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions | TTR, PRNP, APP | GRIN2D 4704/4885GRIN3B 4289/4885GRIN1 4214/4885 |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | LENG8, TSG101, CD47 | GRIN2D 4848/4885GRIN3B 4777/4885GRIN1 4751/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | GRIN2D 4446/4885GRIN3B 3295/4885GRIN1 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.